Abstract
Even after the advent of rituximab, clinical outcomes of conventional immuno-chemotherapy for high-risk diffuse large B-cell lymphoma (DLBCL) remain unsatisfactory. We retrospectively evaluated the efficacy and safety of R-Double-CHOP (R-D-CHOP), consisting of rituximab (375 mg/m(2), day -2), cyclophosphamide (750 mg/m(2), day 1, 2), doxorubicin (50 mg/m(2), day 1, 2), vincristine [1.4 mg/m(2) (maximum 2.0 mg/body), day 1], and prednisolone (50 mg/m(2), day 1-5), followed by consolidation high-dose chemotherapy. This treatment was given to 51 de novo DLBCL patients with a median age of 54 (range 19-65), who were categorized as high/high-intermediate risk by the age-adjusted International Prognostic Index. Treatment was given every 3 weeks up to three courses. The overall response and the complete response rate for R-D-CHOP were 94 and 78 %, respectively. A total of 30 responders proceeded to high-dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT), whereas 16 received high-dose methotrexate (HD-MTX) alternatively. The 3-year overall survival and the event-free survival for all patients were 78 and 61 %, respectively. Major adverse events included hematological toxicities, but there were no treatment-re...Continue Reading
References
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
May 1, 1997·The New England Journal of Medicine·A M GianniG Bonadonna
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C HaiounF Reyes
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jun 21, 2002·The New England Journal of Medicine·Andreas RosenwaldUNKNOWN Lymphoma/Leukemia Molecular Profiling Project
Jan 21, 2003·Leukemia & Lymphoma·Tetsuo YamazakiTakashi Horie
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
May 2, 2006·The Lancet Oncology·Michael PfreundschuhUNKNOWN MabThera International Trial Group
Aug 18, 2006·Acta Haematologica·Tetsuo YamazakiKumi Uenogawa
Nov 16, 2006·Blood·Laurie H SehnJoseph M Connors
Jun 8, 2007·Leukemia·C TarellaUNKNOWN Gruppo Italiano Terapie Innovative nei Linfomi
Jan 28, 2009·Annals of Hematology·Keun-Wook LeeDae Seog Heo
Jul 10, 2009·Haematologica·Umberto VitoloUNKNOWN Gruppo Italiano Multiregionale Linfomi e Leucemie (GIMURELL)
Jan 5, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marie-Sarah DilhuydyUNKNOWN Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS)
Jan 13, 2010·International Journal of Hematology·Ritsuko SekiTakashi Okamura
Dec 2, 2010·Blood·Sietse M AukemaPhilip M Kluin
Jun 23, 2011·International Journal of Hematology·Katsuhiro MiuraJin Takeuchi
Nov 21, 2012·Oncology Reports·Noriyoshi IriyamaJin Takeuchi
Nov 22, 2012·The Lancet Oncology·Norbert SchmitzUNKNOWN German High-Grade Lymphoma Study Group (DSHNHL)
Jun 19, 2013·Annals of Hematology·Yu-Chung HuangYuan-Bin Yu
Nov 1, 2013·The New England Journal of Medicine·Patrick J StiffRichard I Fisher
Nov 16, 2013·International Journal of Hematology·Lijuan DengChen Zhang
Nov 23, 2013·Blood·Zheng ZhouJane N Winter
Dec 18, 2013·International Journal of Hematology·Shojiro InanoNobuyoshi Arima
Feb 5, 2014·Leukemia & Lymphoma·Yujin KobayashiMasami Takei
Citations
Apr 14, 2016·Leukemia & Lymphoma·Hiromichi TakahashiMasami Takei
Jul 28, 2016·Virchows Archiv : an International Journal of Pathology·Daisuke KuritaMasami Takei
Oct 7, 2016·Current Treatment Options in Gastroenterology·Galen LeungSeymour Katz
Oct 5, 2018·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Xueying LiTongyu Lin
Sep 27, 2019·Frontiers in Oncology·Dongmei FanDongsheng Xiong